Monoclonal antibodies have become an essential tool in biochemistry, molecular biology, and medicine, and basic and clinical investigators have been using them widely for research, diagnosis, and clinical therapy. The Monoclonal Antibodies Facility (MABF) was formally established in 2003. Its main goal is to produce high-affinity antibodies in a high-throughput and effective manner, while concentrating on quality of product and service. The MABF minimizes extensive hands-on procedures and standardizes protocols to provide accurate results and reproducibility.
Specific aims and long-term objectives are: 1) to produce high-affinity custom monoclonal antibodies for a wide range of research projects;2) to enable investigators to access highly-experienced personnel in hybridoma production and methodologies, and trouble-shoot any antigen or screening-related issues;3) to provide quality services at competitive prices;4) to gain insight, by means of the generated antibodies, into the role that different molecules play in normal and pathological systems, and characterize them for eventual therapy or diagnosis. The MABF occupies 726 sq. ft. in SCRB 1, home to the Center for Cancer Immunology Research (CCIR) on the South Campus which is equipped with customized laboratory services, centralized tissue culture rooms, liquid nitrogen tanks rooms, and glassware washing and sterilization facilities, all of which are available to the MABF. The MABF staff consists of Michel Gilliet, MD, Core Leader, is responsible for the direction of the core and chairs the oversight committee. Dr. Gilliet meets with Dr. Bover and Long Vien regularly concerning the overall operation of the MABF. Laura Bover, PhD, Core Co-Leader, is responsible for the overall operation of the MABF, for progress reports, interest researchers in the use of the facility and assures that procedural and policy changes are vetted with the oversight committee. She is responsible together with Long Vien of the short- and long-term planning and growth of the facility. Long Vien, Core Manager, is responsible for the day-to-day operations of the core. Together with Dr. Bover, he plans and designs technical procedures for the different user requirements. James Wygant, Coordinator Research Laboratory, is responsible for technical procedures and makes the first contact with users. He records all activities of the facility and follows-up with users, gathering information pertaining to publications, and grants used to cover the services. Rosa Munoz, Research Assistant, is responsible for technical procedures (hands-on). Future plans are to redesign our website to provide more information on services and benefits in an effort to reach more researchers inside MDACC. The facility also needs to communicate more broadly about the unique value-added features of its services.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-37S2
Application #
8530392
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
37
Fiscal Year
2012
Total Cost
$2,882
Indirect Cost
$1,058
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Yedururi, Sireesha; Terpenning, Silanath; Gupta, Sanjay et al. (2017) Radiofrequency Ablation of Hepatic Tumor: Subjective Assessment of the Perilesional Vascular Network on Contrast-Enhanced Computed Tomography Before and After Ablation Can Reliably Predict the Risk of Local Recurrence. J Comput Assist Tomogr 41:607-613
Montalban-Bravo, G; Huang, X; Jabbour, E et al. (2017) A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia 31:318-324
Tadros, Audree B; Smith, Benjamin D; Shen, Yu et al. (2017) Ductal Carcinoma In Situ and Margins <2?mm: Contemporary Outcomes With Breast Conservation. Ann Surg :
Ikoma, Naruhiko; Raghav, Kanwal; Chang, George (2017) An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma. Surg Oncol Clin N Am 26:667-687
Alhuraiji, Ahmad; Jain, Nitin (2017) Immunofluorescence staining with an antipromyelocytic leukemia antibody for a rapid diagnosis of acute promyelocytic leukemia. Hematol Oncol Stem Cell Ther 10:33-34
Lin, Heather Y; Bedrosian, Isabelle; Babiera, Gildy V et al. (2017) Using the National Cancer Data Base for quality evaluation to assess adherence to treatment guidelines for nonmetastatic inflammatory breast cancer. Cancer 123:2618-2625
Rozovski, Uri; Harris, David M; Li, Ping et al. (2017) Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex. Mol Cancer Res 15:610-618
Masarova, Lucia; Kantarjian, Hagop; Garcia-Mannero, Guillermo et al. (2017) Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML. Adv Exp Med Biol 995:73-95
Palacios, Cristina; Daniel, Carrie R; Tirado-Gómez, Maribel et al. (2017) Dietary Patterns in Puerto Rican and Mexican-American Breast Cancer Survivors: A Pilot Study. J Immigr Minor Health 19:341-348
Gunther, Jillian R; Chadha, Awalpreet S; Shin, Ui Sup et al. (2017) Preoperative radiation dose escalation for rectal cancer using a concomitant boost strategy improves tumor downstaging without increasing toxicity: A matched-pair analysis. Adv Radiat Oncol 2:455-464

Showing the most recent 10 out of 10289 publications